Saturday 17 October 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.25
1.04
−6.80%
Follow DYN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
13.47 | 22.25 | 19.92 | 12.02 |
Net Debt/EBITDA |
6.09 | 8.29 | 6.53 | 3.78 | |
Debt/Assets |
11.43% | 12.55% | 14.41% | 21.48% | |
Debt/Equity |
0.14 | 0.15 | 0.18 | 0.30 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 1.00 | 1.20 | 0.73 | |
Capex/Depreciation |
(2.55) | (3.64) | (0.79) | (4.63) | |
Interest Coverage |
(39.22) | (36.36) | (29.81) | (39.53) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.64) | (0.87) | (0.88) | (0.80) | |
Cash per Share |
5.58 | 8.65 | 5.89 | 5.43 | |
Shareholders Equity per Share |
4.88 | 7.57 | 5.24 | 4.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.88 | 7.57 | 5.24 | 4.24 | |
Free Cash Flow |
(91.17) | (112.32) | (145.14) | (131.80) | |
Working Capital |
746.41 | 1,075.96 | 969.78 | 859.86 | |
Capital Expenditures |
(0.39) | (0.48) | (0.22) | (1.51) | |
Net Current Asset Value |
630.99 | 911.76 | 806.13 | 646.03 | |
| Other line items | |||||
Quick Ratio |
13.23 | 21.94 | 18.97 | 11.51 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.64) | (0.87) | (0.88) | (0.79) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Average Payables |
9.11 | 7.32 | 8.90 | 13.08 | |
Average Assets |
817.95 | 939.10 | 900.51 | 861.50 | |
Average Common Equity |
698.66 | 800.98 | 767.01 | 636.80 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates